Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 182,568 shares at $0.98 ($171K) on 2025-11-24, disclosed to the SEC on 2025-11-25.
Scheduled sale ($171k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.83 | 41,287 | $34K | 20.0% |
| 2 | $0.98 | 56,992 | $56K | 32.6% |
| 3 | $0.98 | 56,992 | $56K | 32.6% |
| 4 | $0.92 | 27,297 | $25K | 14.7% |
| Total | $0.94 avg | 182,568 | $171K | 100% |
| Filing → |
| HOWL | SELL | 2026-06-10 | $28K | — | Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |